Nasser, Syed M. T. http://orcid.org/0000-0002-4700-862X
Rana, Anas A.
Doffinger, Rainer
Kafizas, Andreas
Khan, Tauseef A.
Nasser, Shuaib
Funding for this research was provided by:
Cambridge University Hospital Research Trust
Article History
Received: 7 July 2022
Accepted: 19 December 2022
First Online: 24 February 2023
Declarations
:
: Ethics approval was overseen by South Central—Berkshire B Research Ethics Committee (IRAS: 285842). All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Ethical review required that, since blood excess to clinical requirements was taken, not requiring additional bleeding of any patients, consent to participate only required information of the study at the time of hospital presentation, in the form of a patient information leaflet, with contact details via email and telephone number for opting out of the study. No patients opted out from the study.
: Not applicable, as this study does not contain identifying images or other personal or clinical details of participants which could compromise anonymity.
: SMTN is a person of significant control in BIOSIRIUS Ltd, which owns patent applications on interleukin-related therapies. SN and RD are board advisors of BIOSIRIUS Ltd. AR, TK and AK have no conflict of interest disclosures to declare.